Literature DB >> 10435017

Insulin resistance in patients with cardiac hypertrophy.

G Paternostro1, D Pagano, T Gnecchi-Ruscone, R S Bonser, P G Camici.   

Abstract

OBJECTIVE: Animal studies suggest that left ventricular hypertrophy might be associated with insulin resistance and alterations in glucose transporters. We have previously demonstrated myocardial insulin resistance in patients with post-ischemic heart failure. The aim was to investigate whether myocardial insulin resistance could be demonstrated in human cardiac hypertrophy in the absence of hypertension, diabetes and coronary artery disease.
METHODS: Eleven normotensive nondiabetic patients with cardiac hypertrophy due to aortic stenosis and angiographically normal coronary arteries were compared to 11 normal volunteers. Myocardial glucose uptake (MGU) was measured with positron emission tomography and [18F]2-fluoro-2-deoxy-D-glucose during fasting (low insulinemia) or during euglycemic-hyperinsulinemic clamp (physiologic hyperinsulinemia). Myocardial biopsies were obtained in order to investigate changes in insulin-independent (GLUT-1) and insulin-dependent (GLUT-4) glucose transporters.
RESULTS: During fasting, plasma insulin (7 +/- 1 vs. 6 +/- 1 mU/l) and MGU (0.12 +/- 0.05 vs. 0.11 +/- 0.04 mumol/min/g) were comparable in patients and controls. By contrast, during clamp, MGU was markedly reduced in patients (0.48 +/- 0.02 vs. 0.70 +/- 0.03 mumol/min/g, p < 0.01) despite similar plasma insulin levels (95 +/- 6 vs. 79 +/- 6 mU/l). A decreased GLUT-4/GLUT-1 ratio was shown by Western blot analysis in patients.
CONCLUSIONS: Insulin resistance seems to be a feature of the hypertrophied heart even in the absence of hypertension, coronary artery disease and diabetes and may be explained, at least in part, by abnormalities in glucose transporters.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435017     DOI: 10.1016/s0008-6363(98)00233-8

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  32 in total

Review 1.  Cellular and molecular regulation of cardiac glucose transport.

Authors:  L H Young; D L Coven; R R Russell
Journal:  J Nucl Cardiol       Date:  2000 May-Jun       Impact factor: 5.952

Review 2.  Targeting myocardial substrate metabolism in heart failure: potential for new therapies.

Authors:  Hossein Ardehali; Hani N Sabbah; Michael A Burke; Satyam Sarma; Peter P Liu; John G F Cleland; Aldo Maggioni; Gregg C Fonarow; E Dale Abel; Umberto Campia; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2012-02       Impact factor: 15.534

3.  Insulin effects on cardiac Na+/Ca2+ exchanger activity: role of the cytoplasmic regulatory loop.

Authors:  María Celeste Villa-Abrille; Agnieszka Sidor; Brian O'Rourke
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

Review 4.  Glucose Transporters in Cardiac Metabolism and Hypertrophy.

Authors:  Dan Shao; Rong Tian
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

Review 5.  Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention.

Authors:  Rui Guo; Sreejayan Nair
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-24       Impact factor: 5.187

6.  An abbreviated hyperinsulinemic-euglycemic clamp results in similar myocardial glucose utilization in both diabetic and non-diabetic patients with ischemic cardiomyopathy.

Authors:  James A Fallavollita; Andrew J Luisi; Edward Yun; Robert A deKemp; John M Canty
Journal:  J Nucl Cardiol       Date:  2010-04-14       Impact factor: 5.952

7.  "Heart failure, whole-body insulin resistance and myocardial insulin resistance: An intriguing puzzle".

Authors:  Paola Gargiulo; Pasquale Perrone-Filardi
Journal:  J Nucl Cardiol       Date:  2016-08-02       Impact factor: 5.952

8.  Quantitative analysis of myocardial glucose utilization in patients with left ventricular dysfunction by means of 18F-FDG dynamic positron tomography and three-compartment analysis.

Authors:  Koichi Morita; Chietsugu Katoh; Keiichiro Yoshinaga; Kazuyuki Noriyasu; Megumi Mabuchi; Takahiro Tsukamoto; Hiroyuki Kageyama; Tohru Shiga; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-18       Impact factor: 9.236

9.  Diabetic cardiomyopathy: ongoing controversies in 2012.

Authors:  P M Seferović; I Milinković; A D Ristić; J P Seferović Mitrović; K Lalić; A Jotić; V Kanjuh; N Lalić; B Maisch
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

10.  FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases.

Authors:  Yan G Ni; Na Wang; Dian J Cao; Nita Sachan; David J Morris; Robert D Gerard; Makoto Kuro-O; Beverly A Rothermel; Joseph A Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.